Alicia Kowalchuk, Tiffany G Ostovar-Kermani, Kylie Schaper, Larissa Grigoryan, Jacqueline M Hirth, Maria Carmenza Mejia, Kiara K Spooner, Roger J Zoorob
Factors associated with intention to implement SBI and SUD treatment: a survey of primary care clinicians in Texas enrolled in an online course
BMC primary care
current clinical therapeutic efficacy treatment osteo rheumatoidarthritis obviously limited although mesenchymal stem cells mscs considered source promising regenerative therapy unmodified genetically engineered mscs injected vivo restrict clinical utility low drug efficacy unpredicted side effect respectively herein strategy enhance migration efficacy mscs inflamed joints via inflammationmediated education process demonstrated reinforce limited antiinflammatory activity mscs gold nanostar loaded triamcinolone conjugated msc furthermore nearinfrared laserassisted photothermal therapy ptt induced gold nanostar significantly elevates antiinflammatory efficacy developed drugs even advanced stage arthritis model immunological regulation mechanism study ptt first suggested study expression interleukin 22 receptor implicated pathogenesis arthritis downregulated lymphocytes ptt th17 differentiation nave cd4 cell inhibited collectively inflammationtargeting mscs conjugated triamcinoloneloaded gold nanostar edumscsausta promote repolarization macrophages decrease neutrophil recruitment joints addition edumscsausta significantly alleviate arthritisassociated pain improve general locomotor activity importantly induce cartilage regeneration even severe stages arthritis model